2023 - Research.com Best Female Scientist Award
2022 - Research.com Best Female Scientist Award
Jane F. Apperley combines topics linked to Cohort with her work on Internal medicine. In her articles, she combines various disciplines, including Immunology and Cell biology. By researching both Cell biology and Immunology, she produces research that crosses academic boundaries. Jane F. Apperley performs multidisciplinary study in the fields of Oncology and Gastroenterology via her papers. Jane F. Apperley integrates many fields in her works, including Gastroenterology and Internal medicine. Jane F. Apperley frequently studies issues relating to Surgery and Transplantation. Her Surgery study frequently draws connections to other fields, such as Transplantation. She conducts interdisciplinary study in the fields of Genetics and Gene through her works. She performs integrative Gene and Genetics research in her work.
Her research on Internal medicine often connects related areas such as Disease. Her research brings together the fields of Internal medicine and Disease. Jane F. Apperley integrates several fields in her works, including Oncology and Gastroenterology. She integrates several fields in her works, including Gastroenterology and Oncology. Her study deals with a combination of Genetics and Cancer research. Her Cancer research study frequently draws connections to adjacent fields such as Imatinib. Jane F. Apperley combines Imatinib and Nilotinib in her research. As part of her studies on Nilotinib, she often connects relevant areas like Myeloid leukemia. Her research ties Imatinib mesylate and Myeloid leukemia together.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.
Joan BladÉ;Diana Samson;Donna Reece;Jane Apperley.
British Journal of Haematology (1998)
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Michele Baccarani;Michael W. Deininger;Gianantonio Rosti;Andreas Hochhaus.
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Michele Baccarani;Giuseppe Saglio;John Goldman;Andreas Hochhaus.
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
Michele Baccarani;Jorge Cortes;Fabrizio Pane;Dietger Niederwieser.
Journal of Clinical Oncology (2009)
Defining the intensity of conditioning regimens: working definitions.
Andrea Bacigalupo;Karen Ballen;Doug Rizzo;Sergio Giralt.
Biology of Blood and Marrow Transplantation (2009)
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
Jorge E. Cortes;D. W. Kim;J. Pinilla-Ibarz;P. Le Coutre.
The New England Journal of Medicine (2013)
Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib
David Marin;Alexandra Bazeos;Francois Xavier Mahon;Lina Eliasson.
Journal of Clinical Oncology (2010)
Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation
A. Gratwohl;J. Hermans;J. Goldman;W. Arcese.
The Lancet (1998)
Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia
Jane F Apperley.
Lancet Oncology (2007)
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy
Andreas Hochhaus;Hagop M. Kantarjian;Michele Baccarani;Jeffrey H. Lipton.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: